Current status of the second-look operation in ovarian cancer.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy; D006801:Humans; D010535:Laparoscopy; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D012086:Reoperation; D012509:Sarcoma / Q000628:therapy; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine
D000970:Antineoplastic Agents; D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine